文献速递妇科肿瘤

前哨淋巴结活检与淋巴结清扫术在子宫内膜癌分期中的比较(FIRES试验):一项多中心、前瞻性、队列研究

A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.
PubMed 文献 · Lancet Oncol · 2017-02-01

FIRES多中心前瞻性队列研究纳入385例临床I期子宫内膜癌患者,评估吲哚菁绿前哨淋巴结定位对比完全淋巴结清扫检测转移的敏感性和阴性预测值。293例成功定位,41例淋巴结阳性,前哨淋巴结检出敏感性97.2%(95%CI 85.0-100),阴性预测值99.6%(97.9-100)。

要点

  • 前哨淋巴结定位检测子宫内膜癌转移的敏感性为97.2%,阴性预测值为99.6%。
  • 22例发生严重不良事件,仅1例(输尿管损伤)与研究干预相关。
  • 前哨淋巴结活检在3%的淋巴结阳性患者中未能识别转移。

核心结论

  • 吲哚菁绿定位的前哨淋巴结在检测子宫内膜癌转移方面具有高度诊断准确性,可安全替代淋巴结清扫术用于子宫内膜癌分期。
  • 前哨淋巴结活检将在3%的淋巴结阳性患者中未能识别转移,但有可能使更少的患者暴露于完全淋巴结清扫术的并发症。

研究设计与样本

  • FIRES为多中心、前瞻性、队列研究,在美国10个中心(三级学术中心和非学术社区中心)由18名外科医生参与。
  • 纳入临床I期、所有组织学类型和级别的子宫内膜癌患者,接受机器人分期手术。
  • 患者接受标准化宫颈注射吲哚菁绿及前哨淋巴结定位,随后行盆腔淋巴结清扫术,伴或不伴腹主动脉旁淋巴结清扫术。
  • 阴性前哨淋巴结(苏木精-伊红染色切片)进一步行细胞角蛋白免疫组化超分期。
  • 主要终点为基于前哨淋巴结检测转移的敏感性,定义为成功定位的前哨淋巴结的淋巴结阳性患者中,前哨淋巴结正确识别转移的比例;至少定位一个前哨淋巴结的患者纳入主要分析(符合方案)。

主要发现

  • 2012年8月1日至2015年10月20日共入组385例患者。
  • 340例患者行前哨淋巴结定位及完全盆腔淋巴结清扫术,其中196例(58%)行腹主动脉旁淋巴结清扫术。
  • 293例(86%)患者成功定位至少一个前哨淋巴结。
  • 41例(12%)患者淋巴结阳性,其中36例至少有一个定位的前哨淋巴结;这36例中35例(97%)在前哨淋巴结中识别出转移。
  • 检测淋巴结阳性疾病的敏感性为97.2%(95%CI 85.0-100),阴性预测值为99.6%(97.9-100)。

关键数值与推荐

  • 主要终点敏感性为97.2%(95%CI 85.0-100),阴性预测值为99.6%(95%CI 97.9-100)。
  • 293例(86%)患者成功定位至少一个前哨淋巴结;41例(12%)淋巴结阳性,其中36例有至少一个定位的前哨淋巴结。

临床怎么用

  • 作者认为,吲哚菁绿定位的前哨淋巴结在检测子宫内膜癌转移方面具有高度诊断准确性,可安全替代淋巴结清扫术用于子宫内膜癌分期。
  • 作者指出,前哨淋巴结活检将在3%的淋巴结阳性患者中未能识别转移,但有可能使更少的患者暴露于完全淋巴结清扫术的并发症。

局限性

  • 作者指出前哨淋巴结活检将在3%的淋巴结阳性患者中未能识别转移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sentinel-lymph-node mapping has been advocated as an alternative staging technique for endometrial cancer. The aim of this study was to measure the sensitivity and negative predictive value of sentinel-lymph-node mapping compared with the gold standard of complete lymphadenectomy in detecting metastatic disease for endometrial cancer. METHODS: In the FIRES multicentre, prospective, cohort study patients with clinical stage 1 endometrial cancer of all histologies and grades undergoing robotic staging were eligible for study inclusion. Patients received a standardised cervical injection of indocyanine green and sentinel-lymph-node mapping followed by pelvic lymphadenectomy with or without para-aortic lymphadenectomy. 18 surgeons from ten centres (tertiary academic and community non-academic) in the USA participated in the trial. Negative sentinel lymph nodes (by haematoxylin and eosin staining on sections) were ultra-staged with immunohistochemistry for cytokeratin. The primary endpoint, sensitivity of the sentinel-lymph-node-based detection of metastatic disease, was defined as the proportion of patients with node-positive disease with successful sentinel-lymph-node mapping who had metastatic disease correctly identified in the sentinel lymph node. Patients who had mapping of at least one sentinel lymph node were included in the primary analysis (per protocol). All patients who received study intervention (injection of dye), regardless of mapping result, were included as part of the assessment of mapping and in the safety analysis in an intention-to-treat manner. The trial was registered with ClinicalTrials.gov, number NCT01673022 and is completed and closed. FINDINGS: Between Aug 1, 2012, and Oct 20, 2015, 385 patients were enrolled. Sentinel-lymph-node mapping with complete pelvic lymphadenectomy was done in 340 patients and para-aortic lymphadenectomy was done in 196 (58%) of these patients. 293 (86%) patients had successful mapping of at least one sentinel lymph node. 41 (12%) patients had positive nodes, 36 of whom had at least one mapped sentinel lymph node. Nodal metastases were identified in the sentinel lymph nodes of 35 (97%) of these 36 patients, yielding a sensitivity to detect node-positive disease of 97·2% (95% CI 85·0-100), and a negative predictive value of 99·6% (97·9-100). The most common grade 3-4 adverse events or serious adverse events were postoperative neurological disorders (4 patients) and postoperative respiratory distress or failure (4 patients). 22 patients had serious adverse events, with one related to the study intervention: a ureteral injury incurred during sentinel-lymph-node dissection. INTERPRETATION: Sentinel lymph nodes identified with indocyanine green have a high degree of diagnostic accuracy in detecting endometrial cancer metastases and can safely replace lymphadenectomy in the staging of endometrial cancer. Sentinel lymph node biopsy will not identify metastases in 3% of patients with node-positive disease, but has the potential to expose fewer patients to the morbidity of a complete lymphadenectomy. FUNDING: Indiana University Health, Indiana University Health Simon Cancer Center, and the Indiana University Department of Obstetrics and Gynecology.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017. PMID: 28159465. doi:10.1016/S1470-2045(17)30068-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。